T-Therapeutics Secures $91 Million to Advance Bispecific Therapies
November 18, 2025, 9:34 pm
T-Therapeutics boosts Series A to $91M. New funds will push cancer, autoimmune bispecifics to trials. OpTiMus platform aims to unlock undruggable targets. Investors show strong confidence.
Cambridge-based T-Therapeutics has significantly expanded its Series A funding. The total now stands at $91 million. An additional $32 million was secured. New and existing investors participated. The company focuses on T cell receptor (TCR) therapeutics. These target cancer and autoimmune diseases.
The new capital will accelerate clinical development. T-Therapeutics is advancing its pipeline. The pipeline features first-in-class TCR CD3 bispecifics. These therapies aim to transform treatment.
Tencent and BGF are new investors. They join returning backers. Sofinnova Partners, F Prime, and Digitalis Ventures continue support. Cambridge Innovation Capital, Sanofi Ventures, and the University of Cambridge Venture Fund also participated. The expanded Series A signals strong investor confidence.
The funding will boost core programs. T-Therapeutics focuses on oncology and immunology. The lead oncology asset targets pan-tumor drivers. This could impact multiple solid tumor types. The lead immunology program targets pan-autoimmune diseases. It aims for precision immune reset. This involves selectively depleting pathogenic immune cells.
T-Therapeutics plans to explore new therapeutic strategies. T cell subset depletion is one area of focus. This could offer novel treatment approaches.
The company's pipeline relies on the OpTiMus platform. This platform generates human TCRs. These TCRs have high specificity. They can engage intracellular targets. These targets were once considered undruggable.
These TCRs are paired with CD3 T cell engagers. These engagers are engineered for potency. They also prioritize safety and favorable pharmacokinetics. This results in bispecific candidates.
T-Therapeutics originated from the University of Cambridge. The team possesses deep expertise. This includes mouse genome engineering. Expertise in single-cell genomics also exists. Drug development, machine learning, and structural biology are also key areas.
T-Therapeutics aims to address critical unmet needs. Cancer and autoimmune diseases are the focus. The OpTiMus platform unlocks previously undruggable targets. Bispecifics are the core therapeutic approach.
The funding landscape in Europe is active. Adcytherix secured significant funding. Adaptam Therapeutics also raised capital. These companies operate in similar fields. They demonstrate investor interest in immunotherapy. T-Therapeutics' Series A is a major portion of this activity.
T-Therapeutics harnesses T cell biology. It seeks to create safe, effective treatments. The company combines TCRs and CD3 engagers. This forms bispecific drug candidates.
The company's team has a strong track record. They have built successful drug discovery businesses. They translate science into medicine. The investor syndicate is world-class. T-Therapeutics is well-positioned for success.
The additional funds will drive the pipeline. The goal is to advance TCR-CD3 bispecifics to clinical trials. This includes exploring new therapeutic strategies.
The lead immunology program is designed for precision. It aims to reset the immune system. Selective depletion of pathogenic cells is the key. This approach targets the root of autoimmune diseases.
"
T-Therapeutics Secures $91 Million to Advance Bispecific Therapies
Cambridge-based T-Therapeutics has significantly expanded its Series A funding. The total now stands at $91 million. An additional $32 million was secured. New and existing investors participated. The company focuses on T cell receptor (TCR) therapeutics. These target cancer and autoimmune diseases.
New Funds for Clinical Development
The new capital will accelerate clinical development. T-Therapeutics is advancing its pipeline. The pipeline features first-in-class TCR CD3 bispecifics. These therapies aim to transform treatment.
Investor Confidence Grows
Tencent and BGF are new investors. They join returning backers. Sofinnova Partners, F Prime, and Digitalis Ventures continue support. Cambridge Innovation Capital, Sanofi Ventures, and the University of Cambridge Venture Fund also participated. The expanded Series A signals strong investor confidence.
Targeting Cancer and Autoimmune Diseases
The funding will boost core programs. T-Therapeutics focuses on oncology and immunology. The lead oncology asset targets pan-tumor drivers. This could impact multiple solid tumor types. The lead immunology program targets pan-autoimmune diseases. It aims for precision immune reset. This involves selectively depleting pathogenic immune cells.
Exploring New Strategies
T-Therapeutics plans to explore new therapeutic strategies. T cell subset depletion is one area of focus. This could offer novel treatment approaches.
OpTiMus Platform: Unlocking the Undruggable
The company's pipeline relies on the OpTiMus platform. This platform generates human TCRs. These TCRs have high specificity. They can engage intracellular targets. These targets were once considered undruggable.
Next-Generation CD3 Engagers
These TCRs are paired with CD3 T cell engagers. These engagers are engineered for potency. They also prioritize safety and favorable pharmacokinetics. This results in bispecific candidates.
University of Cambridge Spin-Out
T-Therapeutics originated from the University of Cambridge. The team possesses deep expertise. This includes mouse genome engineering. Expertise in single-cell genomics also exists. Drug development, machine learning, and structural biology are also key areas.
Addressing Unmet Medical Needs
T-Therapeutics aims to address critical unmet needs. Cancer and autoimmune diseases are the focus. The OpTiMus platform unlocks previously undruggable targets. Bispecifics are the core therapeutic approach.
European Immuno-Oncology Landscape
The funding landscape in Europe is active. Adcytherix secured significant funding. Adaptam Therapeutics also raised capital. These companies operate in similar fields. They demonstrate investor interest in immunotherapy. T-Therapeutics' Series A is a major portion of this activity.
TCR Technology and Bispecific Candidates
T-Therapeutics harnesses T cell biology. It seeks to create safe, effective treatments. The company combines TCRs and CD3 engagers. This forms bispecific drug candidates.
Leadership and Expertise
The company's team has a strong track record. They have built successful drug discovery businesses. They translate science into medicine. The investor syndicate is world-class. T-Therapeutics is well-positioned for success.
Driving Pipeline Towards the Clinic
The additional funds will drive the pipeline. The goal is to advance TCR-CD3 bispecifics to clinical trials. This includes exploring new therapeutic strategies.
Precision Immune Reset
The lead immunology program is designed for precision. It aims to reset the immune system. Selective depletion of pathogenic cells is the key. This approach targets the root of autoimmune diseases.
"